SEC FORM 3

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kestenberg-Messina Kaitlin M.

(Last)

(First)

(Middle)

C/O ADMA BIOLOGICS, INC.

5800 PARK OF COMMERCE BLVD. NW,

(Street)

BOCA RATON

33487

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2024

3. Issuer Name and Ticker or Trading Symbol
ADMA BIOLOGICS, INC. [ ADMA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	COO and SVP, Compliance

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	114,275⁽¹⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Restricted Stock Units	⁽²⁾	⁽²⁾	Common Stock	5,000	$0⁽²⁾	D
Restricted Stock Units	⁽³⁾	⁽³⁾	Common Stock	25,000	$0⁽³⁾	D
Restricted Stock Units	⁽⁴⁾	⁽⁴⁾	Common Stock	20,000	$0⁽⁴⁾	D
Restricted Stock Units	⁽⁵⁾	⁽⁵⁾	Common Stock	71,250	$0⁽⁵⁾	D
Restricted Stock Units	⁽⁶⁾	⁽⁶⁾	Common Stock	30,000	$0⁽⁶⁾	D
Stock Option (Right to Buy)	⁽⁷⁾	01/30/2025	Common Stock	5,000	$10.8	D
Stock Option (Right to Buy)	⁽⁸⁾	07/30/2025	Common Stock	2,500	$8.98	D
Stock Option (Right to Buy)	⁽⁹⁾	02/14/2027	Common Stock	5,000	$5	D
Stock Option (Right to Buy)	⁽¹⁰⁾	05/03/2028	Common Stock	5,000	$4.72	D
Stock Option (Right to Buy)	⁽¹¹⁾	10/09/2028	Common Stock	6,650	$5.94	D
Stock Option (Right to Buy)	⁽¹²⁾	06/05/2029	Common Stock	1,563	$4.31	D
Stock Option (Right to Buy)	⁽¹³⁾	06/05/2029	Common Stock	937	$4.31	D
Stock Option (Right to Buy)	⁽¹⁴⁾	03/10/2030	Common Stock	20,876	$2.59	D
Stock Option (Right to Buy)	⁽¹⁵⁾	08/19/2030	Common Stock	13,334	$2.83	D
Stock Option (Right to Buy)	⁽¹⁶⁾	02/25/2031	Common Stock	30,000	$2.35	D
Stock Option (Right to Buy)	⁽¹⁷⁾	07/19/2031	Common Stock	10,000	$1.55	D

Explanation of Responses:

1. Includes 114,275 shares acquired pursuant to the vesting of restricted stock units ("RSUs").

2. On February 25, 2021, the Company granted the reporting person 20,000 RSUs, 5,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

3. On September 28, 2021, the Company granted the reporting person 100,000 RSUs, 25,000 of which are currently unvested, with 50% vesting on December 31, 2022 and the remaining vesting quarterly from March 31, 2023 to December 31, 2024, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

4. On March 7, 2022, the Company granted the reporting person 40,000 RSUs, 20,000 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

5. On March 6, 2023, the Company granted the reporting person 95,000 RSUs, 71,250 of which are currently unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

6. On July 24, 2023, the Company granted the reporting person 30,000 RSUs, all of which remain unvested, with 25% vesting on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting.

7. The incentive stock options were granted to the reporting person on January 30, 2015, which are fully vested in accordance with the Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (the "Plan").

8. The incentive stock options were granted to the reporting person on July 30, 2015, which are fully vested in accordance with the Plan.

9. The incentive stock options were granted to the reporting person on February 14, 2017, which are fully vested in accordance with the Plan.

10. The incentive stock options were granted to the reporting person on May 3, 2018, which are fully vested in accordance with the Plan.

11. The incentive stock options were granted to the reporting person on October 9, 2018, which are fully vested in accordance with the Plan.

12. The incentive stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan.

13. The non-qualified stock options were granted to the reporting person on June 5, 2019, which are fully vested in accordance with the Plan.

14. The incentive stock options were granted to the reporting person on March 10, 2020, which are fully vested in accordance with the Plan.

15. The incentive stock options were granted to the reporting person on August 19, 2020, 2,084 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.

16. The incentive stock options were granted to the reporting person on February 25, 2021, 6,875 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.

17. The incentive stock options were granted to the reporting person on July 19, 2021, 3,334 of which are currently unvested. The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, subject to the reporting person's continued service as of the applicable vesting date.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Kaitlin M. Kestenberg-Messina, by Adam S. Grossman as attorney-in-fact	04/02/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

New insider Kestenberg-Messina Kaitlin M. claimed ownership of 114,275 shares (SEC Form 3)